Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies

OBJECTIVE: The risk of cardiovascular disease (CVD) is higher in patients with psoriatic arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Because tofacitinib increases circulating lipid levels in some patients, we evaluated C...

Descripción completa

Detalles Bibliográficos
Autores principales: Gladman, Dafna D., Charles‐Schoeman, Christina, McInnes, Iain B., Veale, Douglas J., Thiers, Bruce, Nurmohamed, Mike, Graham, Dani, Wang, Cunshan, Jones, Thomas, Wolk, Robert, DeMasi, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764856/
https://www.ncbi.nlm.nih.gov/pubmed/31112005
http://dx.doi.org/10.1002/acr.23930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764856/
https://www.ncbi.nlm.nih.gov/pubmed/31112005
http://dx.doi.org/10.1002/acr.23930

Ejemplares similares